KLK6 and Alzheimer disease: Last, with the opportunity provided through the longitudinal nature of cohort 2, we were able to assess whether plasma and CSF KLK6 levels increase over time (24 months) in (1) patients with MCI that was stable over 2 years or in those converting to AD and (2) patients with AD.